Pliant Therapeutics
PLRX
140 hedge funds and large institutions have $78.5M invested in Pliant Therapeutics in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 42 increasing their positions, 39 reducing their positions, and 50 closing their positions.
2,040% more call options, than puts
Call options by funds: $214K | Put options by funds: $10K
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
11.88% less ownership
Funds ownership: 106.42% → 94.53% (-12%)
13% less funds holding
Funds holding: 160 → 140 (-20)
36% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 50
83% less funds holding in top 10
Funds holding in top 10: 6 → 1 (-5)
91% less capital invested
Capital invested by funds: $853M → $78.5M (-$774M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$36.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$18.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$14.5M |
| 4 |
Morgan Stanley
New York
|
+$13.8M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$42.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27.6M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$26.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.4M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$22.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RS
176
R Squared
Central,
Hong Kong
| – | -$32.8K | -2,490 | Closed |
|
|
VCM
177
Versant Capital Management
Phoenix,
Arizona
| – | -$8.85K | -672 | Closed |
|
178
US Bancorp
Minneapolis,
Minnesota
| – | -$5.98K | -454 | Closed |
|
|
GI
179
GAMMA Investing
Foster City,
California
| – | -$2.38K | -181 | Closed |
|
|
S
180
SignatureFD
Atlanta,
Georgia
| – | -$1.63K | -124 | Closed |
|
181
Creative Planning
Overland Park,
Kansas
| – | -$1.44K | -109 | Closed |
|
|
WTA
182
Washington Trust Advisors
Wellesley,
Massachusetts
| – | -$856 | -65 | Closed |
|
|
SIC
183
Salem Investment Counselors
Winston Salem,
North Carolina
| – | -$791 | -60 | Closed |
|
|
AAP
184
Arax Advisory Partners
Denver,
Colorado
| – | -$606 | -46 | Closed |
|
|
LC
185
Lindbrook Capital
Calabasas,
California
| – | -$329 | -25 | Closed |
|
|
CPG
186
Cornerstone Planning Group
Fairfield,
New Jersey
| – | -$264 | -24 | Closed |
|
|
WCM
187
WealthTrak Capital Management
Virginia Beach,
Virginia
| – | -$132 | -10 | Closed |
|
|
AF
188
Allworth Financial
Folsom,
California
| – | -$22 | -2 | Closed |
|
PLRX Hedge Fund Activity: Q1 2025 in Review
140 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q1 2025, worth a combined $78.5M — down 91% from $853M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of PLRX and 32 opened new positions — a net loss of 18 holders — while 39 trimmed existing stakes and 42 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $36.4M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $42.1M sold.
- 140 institutional investors held Pliant Therapeutics (PLRX) as of Q1 2025, down from 160 in Q4 2024.
- Funds reported $78.5M of Pliant Therapeutics stock for Q1 2025, down 91% quarter-over-quarter.
- 32 funds opened new Pliant Therapeutics positions in Q1 2025 and 50 closed out, a net change of -18 holders.
- The largest Pliant Therapeutics buyer in Q1 2025 was Tang Capital Management, an estimated $36.4M added.
- The largest Pliant Therapeutics seller in Q1 2025 was Paradigm Biocapital Advisors, an estimated $42.1M sold.
Based on aggregated 13F filings for Q1 2025.